Syndromes Without a Name Bring Labs an Uphill Battle
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?
G2 Intelligence managing editor Rachel Muenz chats with lab leader Stephanie Whitehead about recent developments affecting clinical labs.
The panel recently said there was still not enough evidence to properly assess the harms and benefits of such screening.
A recent CDC report concludes that disruptions to HIV testing due to the COVID-19 pandemic compromised America’s ability to prevent the disease.
According to a recent OIG report, fewer Medicare Part B beneficiaries received lab tests during the first 10 months of the pandemic.
Advances in MALDI time-of-flight mass spectrometry have significantly expanded its use in high-throughput diagnostic labs.
Video telehealth during the early period of the COVID-19 quarantine was actually highly effective in providing accurate diagnoses, research shows.
While new FDA clearances of blood-based early detection tests for Alzheimer’s represent significant progress, limitations remain.
Two recent studies show that most people see telehealth as a supplement to in-person visits, rather than a replacement.
A new study suggests that this is a viable idea, particularly in the context of diabetes screening in a Latinx community.
Despite the emergence and rise of new Omicron variants, COVID-19 testing has declined as much as 90 percent, according to some reports.